Brand Name

Alunbrig

Generic Name
Brigatinib
View Brand Information
FDA approval date: April 28, 2017
Classification: Kinase Inhibitor
Form: Tablet, Kit

What is Alunbrig (Brigatinib)?

ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase -positive metastatic non-small cell lung cancer as detected by an FDA-approved test [see Dosage and Administration.
Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Description of Neurocognitive and Psychiatric Disorders Associated With Targeted Therapies Used in the Treatment of Lung Cancers With ALK/ROS1 Fusion and Their Impact on Patients' Quality of Life: Construction of an Experimental Patient-researcher Collaborative Care and Research Pathway

Summary: Targeted cancer therapies have a higher therapeutic index than chemotherapy and are prescribed to tens of thousands of patients in France each year. These treatments modify often ubiquitous signaling pathways involved in neuronal synaptic plasticity, the cellular substrate of cognitive and psychiatric functions. Neurocognitive and psychiatric disorders associated with targeted therapies are poorly...

A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Summary: This is an open-label, phase I-II dose-escalation and expansion study designed to define the recommended dose of brigatinib as monotherapy in pediatric and young adult patients with ALK+ ALCL, IMT or other solid tumors and to evaluate the pharmacokinetics (PK), (long-term) safety, and efficacy of brigatinib in these children.

General Use-results Survey of Alunbrig Tablets Non-small Cell Lung Cancer

Summary: This study is a survey in Japan of Brigatinib tablets used to treat Japanese people with non-small cell lung cancer. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study. The main aim of the study is to check for side effects related to lung disease from Brigatinib. During the study, pa...

Brand Information

Alunbrig (brigatinib)
1INDICATIONS AND USAGE
ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test
2DOSAGE FORMS AND STRENGTHS
  • 180 mg: oval, white to off-white film-coated tablets with "U13" debossed on one side and plain on the other side
  • 90 mg: oval, white to off-white film-coated tablets with "U7" debossed on one side and plain on the other side
  • 30 mg: round, white to off-white film-coated tablets with "U3" debossed on one side and plain on the other side
3CONTRAINDICATIONS
None.
4ADVERSE REACTIONS
The following adverse reactions are discussed in greater detail in other sections of the prescribing information:
  • Interstitial Lung Disease (ILD)/Pneumonitis
  • Hypertension
  • Bradycardia
  • Visual Disturbance
  • Creatine Phosphokinase (CPK) Elevation
  • Pancreatic Enzymes Elevation
  • Hepatotoxicity
  • Hyperglycemia
  • Photosensitivity
4.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
5DESCRIPTION
Brigatinib is a kinase inhibitor. The chemical name for brigatinib is 5-chloro-N
Chemical Structure
Brigatinib is an off-white to beige/tan solid. The pK
ALUNBRIG is supplied for oral use as film-coated tablets containing 180 mg, 90 mg or 30 mg of brigatinib and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, sodium starch glycolate (Type A), magnesium stearate, and hydrophobic colloidal silica. The tablet coating consists of talc, polyethylene glycol, polyvinyl alcohol, and titanium dioxide.
6HOW SUPPLIED/STORAGE AND HANDLING
180 mg tablets: oval, white to off-white film-coated tablets with "U13" debossed on one side and plain on the other side; available in:
90 mg tablets: oval, white to off-white film-coated tablets with "U7" debossed on one side and plain on the other side; available in:
30 mg tablets: round, white to off-white film-coated tablets with "U3" debossed on one side and plain on the other side; available in:
90 mg / 7 count tablets (NDC 63020-090-07) and 180 mg / 23 count tablets (NDC 63020-180-23) are also available in a single carton as a one-month initiation pack:
7PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information).
8PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Carton
NDC 63020-113-30
ALUNBRIG
30 mg
Rx Only
30 Tablets
PRINCIPAL DISPLAY PANEL - 30 mg Tablet Bottle Carton
9PRINCIPAL DISPLAY PANEL - 90 mg Tablet Bottle Carton
NDC 63020-090-30
ALUNBRIG
90 mg
Rx Only
30 Tablets
PRINCIPAL DISPLAY PANEL - 90 mg Tablet Bottle Carton
10PRINCIPAL DISPLAY PANEL - 180 mg Tablet Bottle Carton
NDC 63020-180-30
ALUNBRIG
180 mg
Rx Only
30 Tablets
PRINCIPAL DISPLAY PANEL - 180 mg Tablet Bottle Carton
11PRINCIPAL DISPLAY PANEL - Kit Carton
NDC 63020-198-30
INITIATION PACK
ALUNBRIG
Rx Only | Oral Use
Usual Dose: One 90 mg tablet orally once daily for the first 7 days;
90 mg
7 Tablets
Take 1 tablet on
180 mg
23 Tablets
Take 1 tablet on
PRINCIPAL DISPLAY PANEL - Kit Carton